Dato-DXd’s Intracranial Efficacy in NSCLC: Insights from TROPION-Lung01
Jacob Sands, MD
Aaron Lisberg, MD
Giredestrant and Everolimus in HR+/HER2- Breast Cancer: Insights from evERA
Pavani Chalasani, MD, MPH
Erica L. Mayer, MD, MPH
SERENA-6: Assessing Camizestrant’s Impact in HR+/HER2- Breast Cancer
Growth Recovery After Tovorafenib in Pediatric Low-Grade Gliomas: New Data
Alexandria May, PharmD, BCPS
Daniel Landi, MD
Unmet Needs in Endometrial Cancer: Bridging Gaps in Treatment and Equity
Brian Slomovitz, MD
Dexamethasone Timing and Infusion Reactions in HER2+ Breast Cancer
The Future of Immunotherapy: Advancing Care in Endometrial Cancer
Casey Cosgrove, MD
Routes Reconsidered: A Case-Based Debate in SERD Selection
Giuseppe Curigliano, MD, PhD
Komal Jhaveri, MD, FACP
Spotlight on Asia-Pacific: Practice Beyond Borders
Hiraji Iwata, MD, PhD
Safety of CDK4/6 Inhibitors: Anticipation, Prevention, and Management of Adverse Events
Spotlight on Latin America: Closing the Gap
Cynthia Villarreal-Garza, MD, DSc
The Future of Oral SERDs: Combination Strategies
Breaking Down the Benchmarks: Pivotal Data on First-Line CDK4/6 Inhibitors
Beyond Fulvestrant: Oral SERDs Redefining ER Targeting
Doublet or Triplet? A Case-Based Debate in First-Line Choices for HR+/HER2- mBC
Real-World Cases in Pediatric Low-Grade Glioma: Exploring Targeted Therapies
Angela Waanders, MD, MPH, MS
Ashley S. Margol, MD, MS
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.